A new study led by researchers at Rhode Island Hospital in collaboration with the University of Rhode Island (URI) and EpiVax. Inc, a privately owned vaccine development company in Providence, RI, has identified a potential vaccine capable of reducing colonization of Helicobacter pylori (H. pylori) -- a known cause of gastritis, ulcer disease and cancer. Their findings appear online in advance of print in the journal Vaccine.
Because the colonization of H. pylori has far-reaching health consequences, it represents a significant public health challenge. Current treatments use multiple antibiotics in combination with acid suppression medications to eradicate it. Due to an increase in antibiotic resistance, it is now more difficult to eliminate, and the development of a vaccine as an alternative therapy is of increased interest.
More at
Science Daily